Generic drug manufacturer Glenmark Pharmaceuticals executed a debut $200 million bond issue on Monday, taking advantage of rising demand for Indian high-yield deals to price significantly through brokers' fair value estimates.
The BBBB rated deal represents the third Indian high-yield offering in the space of two months, following a $300 million issue for BB rated auto parts manufacturer Samvardhana Motherson Auto in mid-June and a $300 million issue for Ba3BB-BB- rated Hexaware in early July.
Each transaction has generated a higher peak order book than the last, with Motherson achieving $1.4 billion in demand, Hexaware $1.9 billion and Glenmark $2.3...
¬ Haymarket Media Limited. All rights reserved.
